ArticleJournal of the European Academy of Dermatology and Venereology : JEADV2026
Reassessing the OX40/OX40L axis in atopic dermatitis after the termination of Rocatinlimab's clinical development program.
Thomas BieberPubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.